Literature DB >> 11841075

Ethnicity and treatment response in schizophrenia: a comparison of 3 ethnic groups.

Robin A Emsley1, Mimi C Roberts, Solomon Rataemane, Janus Pretorius, Piet P Oosthuizen, Jadri Turner, Dana J H Niehaus, Natasha Keyter, Dan J Stein.   

Abstract

BACKGROUND: Numerous cultural and ethnic factors may directly and indirectly influence treatment outcome in schizophrenia. The present study compared the response to antipsychotic treatment in 3 ethnic groups of patients with schizophrenia.
METHOD: Fifty black, 63 mixed descent, and 79 white patients with DSM-IV-diagnosed schizophrenia or schizophreniform disorder who were participants in multinational clinical drug trials were assessed by means of the Positive and Negative Syndrome Scale (PANSS). Treatment response was measured by the change in PANSS total scores and the change in positive, negative, and general psychopathology subscale scores from baseline to 6 weeks. Also, the percentage of responders (defined as > or = 40% reduction in PANSS total scores) was calculated for each group.
RESULTS: Baseline PANSS scores differed significantly, being higher for black and mixed descent patients. Mixed descent patients showed the greatest mean +/- SD percentage reduction in PANSS total score (29.4 +/- 21.6) followed by black (28.4 +/- 14.7) and white (11.4 +/- 27.6) patients. Analysis of covariance revealed a significant effect of ethnicity on the reduction in PANSS total scores (p < .0001). The numbers of responders were 20 mixed descent (32%), 12 black (24%), and 7 white (9%) patients (p = .002).
CONCLUSION: Significant ethnic differences in acute antipsychotic treatment response are demonstrated by this study. Factors such as diet, nutritional status, body mass, and substance use could be important, as well as genetically determined ethnospecific pharmacokinetic and pharmacodynamic differences. Delayed help-seeking may account for the higher baseline scores in the black and mixed descent patients.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11841075     DOI: 10.4088/jcp.v63n0103

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  20 in total

Review 1.  Understanding antipsychotic "atypicality": a clinical and pharmacological moving target.

Authors:  Gary Remington
Journal:  J Psychiatry Neurosci       Date:  2003-07       Impact factor: 6.186

Review 2.  Genetics and psychopharmacology: prospects for individualized treatment.

Authors:  Charles U Nnadi; Joseph F Goldberg; Anil K Malhotra
Journal:  Essent Psychopharmacol       Date:  2005

Review 3.  Contribution of allelic variations to the phenotype of response to antidepressants and antipsychotics.

Authors:  Wolfgang Maier; Astrid Zobel
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2008-03       Impact factor: 5.270

Review 4.  Pharmacogenetics in psychiatry: are we ready for widespread clinical use?

Authors:  Maria J Arranz; Shitij Kapur
Journal:  Schizophr Bull       Date:  2008-08-27       Impact factor: 9.306

5.  Efficacy and Safety of Paliperidone Extended Release 1.5 mg/day-A Double-blind, Placebo- and Active-Controlled, Study in the Treatment of Patients with Schizophrenia.

Authors:  Danielle Coppola; Rama Melkote; Caroline Lannie; Jaskaran Singh; Isaac Nuamah; Srihari Gopal; David Hough; Joseph Palumbo
Journal:  Psychopharmacol Bull       Date:  2011-05-15

Review 6.  Pharmacogenetics of response to antipsychotics in patients with schizophrenia.

Authors:  Maria J Arranz; Margarita Rivera; Janet C Munro
Journal:  CNS Drugs       Date:  2011-11-01       Impact factor: 5.749

7.  Exploring Biologic Predictors Response Disparities to Atypical Antipsychotics among Blacks: A Quasi-Systematic Review.

Authors:  Rebecca N Jerome; Jill M Pulley; Nila A Sathe; Shanthi Krishnaswami; Alyssa B Dickerson; Katherine J Worley; Consuelo H Wilkins
Journal:  Ethn Dis       Date:  2020-04-02       Impact factor: 1.847

8.  Longitudinal treatment outcome of African American and Caucasian patients with first episode psychosis.

Authors:  Huijun Li; Shaun M Eack; Debra M Montrose; Jean M Miewald; Matcheri Keshavan
Journal:  Asian J Psychiatr       Date:  2011-10-12

Review 9.  Is the PANSS used correctly? a systematic review.

Authors:  Michael Obermeier; Rebecca Schennach-Wolff; Sebastian Meyer; Hans-Jürgen Möller; Michael Riedel; Daniela Krause; Florian Seemüller
Journal:  BMC Psychiatry       Date:  2011-07-18       Impact factor: 3.630

10.  Long-acting risperidone injection: efficacy, safety, and cost-effectiveness of the first long-acting atypical antipsychotic.

Authors:  Pierre Chue
Journal:  Neuropsychiatr Dis Treat       Date:  2007-02       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.